Prognostic factors in clinical stage T4N2 locally advanced non-small cell lung cancer.

Purpose: Relatively few studies have focused on T4N2 (stage IIIB) locally advanced non-small cell lung cancer (NSCLC). In this study, we tried to identify prognostic factors for patients with clinical stage T4N2 NSCLC.

Methods: We retrospectively identified 223 patients, of which 168 met the inclusion criteria.

Prolonged progression-free survival with maintenance metronomic oral cyclophosphamide and etoposide treatment in macroscopic residual disease or recurrent/advanced stage ovarian cancer.

Purpose: In ovarian cancer permanent remission may be provided with optimal cytoreductive surgery and adjuvant chemotherapy. However survival is short in patients with residual macroscopic disease after surgery or recurrent ovarian cancer. Applicable maintenance therapies with low toxicity are required to prolong progression-free survival (PFS) for patients with no curative treatment options.

Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab.

Background: The beneficial effects of bevacizumab, a widely used agent in metastatic colorectal cancer (mCRC), on clinical survival have been proven. This study investigated the correlation of the clinical benefits and prognosis with proteinuria and other parameters.

Methods: The study included mCRC patients receiving bevacizumab.

Coexistence of gastric adenocarcinoma and choriocarcinoma: complete response to trastuzumab and chemotherapy.

Gastric choriocarcinoma is a rare neoplasm and usually accompanies gastric adenocarcinoma. The prognosis is poor due to the aggressive course of the disease. A 57-year-old female patient with weight loss and abdominal pain was examined.